1Mackmess MI,Mackmess B,Durrington PN,et al.Paraoxonase:biochemistry,genetics and relationship to plasma lipoproteins.Curr Opin Lipidol.1996,7:69～76.
2Mackmess MI,Abbott S,Durrington PN,et al.The role of high density lipoprotein and lipid-siluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation.Biochem J.1993,294:829～835.
3Durrington PN,Mackness B,Mackness MI.Paraoxonase and atherosclerosis.Arterioscler Thromb Vasc Biol 2001,21:473～80.
5Tomas M,Senti M,Garcia-Faria F,et al.Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients.Arterioscler Thromb Vasc Biol 2000,20:2113～9.
6Saha N,Roy AC,Teo SH,et al.Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins.Clin genet 1991,40:277～282.
7Yamada A,Shoji T,Tahara H,Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population,Metabolism 2001,50:805～11.
8Feingold KR,Memon RA,Moser AH,et al.Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response.Atherosclerosis 1998,139:307～15.
9James RW,Leviev Ⅱ,Righetti A.Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease.Circulation 2000,101:2252～7.
10Turban S,Fuentes F,Ferlic L,et al.A prospective study of paraoxonase gene Q/R192 polymorphism and severity,progression and regression of coronary atherosclerosis,plasma lipid levels,clinical events and response to fluvastatin.Atherosclerosis 2001,154:633～40.
同被引文献22
1[1]Mackness MI, Mackness B, Durington PN, et al. Paraoxonase and coronary heart disease.Curr Opin Lipidol, 1998, 9:319-324.
2[2]Rosenblat M, Hayek T, Hussein K, et al.Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler Thromb Vasc Biol, 2004, 24:175-180.
3[3]Reddy ST, Wadleigh DJ, Grijalva V, et al.Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol, 2001, 21:542-547.
4[4]Deakin S, Leviev T, Guernier S, et al. Simvastatin modulates expression of the PON1gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol,2003, 23:2083-2089.
5[7]Boemi M, Sirolla C, Testa R, et al. Smoking is associated with reduced serum levels of the antioxidant enzyme, paraoxonase, in Type 2 diabetic patients. Diabet Med, 2004,21:423-427.
6[8]Kopprasch S, Pietzsch J, Kuhlisch E, et al.Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. Clin Endocrinol Metab, 2003,88:1711-1716.
7[9]Rozenberg O, Shih DM, Aviram M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol, 2003, 23:461-467.
8[10]Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid ayherosclerotic lesions:PON1 esterase and peroxidase-like activities. Circulation, 2000, 101:2510-2517.
9[11]Jakubowski H, Ambrosius WT, Pratt H. Genetic determinants of homocysteine thiolactonase activity in humans:implications for atherosclerosis. FEBS Lett, 2001, 491:35-39.
10[12]Frank R, Leus M, Wittekoek E, et al.Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia.Atherosclerosis, 2000, 149:371-377.
